See more : Westwing Comércio Varejista S.A. (WEST3.SA) Income Statement Analysis – Financial Results
Complete financial analysis of PaxMedica, Inc. Common Stock (PXMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PaxMedica, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- Grupo Aeroportuario del Centro Norte, S.A.B. de C.V. (OMAB.MX) Income Statement Analysis – Financial Results
- Dijet Industrial Co., Ltd. (6138.T) Income Statement Analysis – Financial Results
- Hennessy Capital Investment Corp. VI (HCVIU) Income Statement Analysis – Financial Results
- Hangzhou Zhongtai Cryogenic Technology Corporation (300435.SZ) Income Statement Analysis – Financial Results
- New Relic, Inc. (NEWR) Income Statement Analysis – Financial Results
PaxMedica, Inc. Common Stock (PXMD)
About PaxMedica, Inc. Common Stock
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.91M | 1.79M | 2.22M | 936.78K | 484.11K |
| General & Administrative | 12.23B | 8.82M | 4.97M | 4.63M | 114.50K |
| Selling & Marketing | -12.22B | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.23M | 8.82M | 4.97M | 4.63M | 114.50K |
| Other Expenses | 0.00 | -5.51M | 173.35K | -53.54K | 0.00 |
| Operating Expenses | 16.15M | 10.60M | 7.20M | 5.57M | 598.61K |
| Cost & Expenses | 16.15M | 10.60M | 7.20M | 5.57M | 598.61K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.17K | 5.24K | 2.81M | 609.46K | 0.00 |
| Depreciation & Amortization | 167.90K | -5.90M | 173.35K | -53.54K | 171.86K |
| EBITDA | -16.15M | -10.60M | -7.20M | -5.62M | -598.61K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.15M | -10.60M | -7.20M | -5.57M | -598.61K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.14M | -4.20M | -3.03M | -2.26M | 0.00 |
| Income Before Tax | -18.29M | -14.80M | -10.23M | -7.83M | -598.61K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -167.90K | 4.19M | 2.81M | 663.00K | -171.86K |
| Net Income | -18.29M | -14.80M | -13.03M | -8.49M | -598.61K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -11.00 | -28.79 | -18.81 | -12.25 | -0.06 |
| EPS Diluted | -11.00 | -28.79 | -18.81 | -12.25 | -0.06 |
| Weighted Avg Shares Out | 1.66M | 514.22K | 692.91K | 692.91K | 10.02M |
| Weighted Avg Shares Out (Dil) | 1.66M | 514.22K | 692.91K | 692.91K | 10.02M |
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman
PaxMedica Announces Closing of $7.0 Million Public Offering
Why Are Stocks Up Today?
Penny Stocks To Buy? 5 To Watch Right Now
Why Is PaxMedica (PXMD) Stock Up 57% Today?
Why Is PaxMedica (PXMD) Stock Down 40% Today?
PaxMedica Announces Pricing of $7.0 Million Public Offering
PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data
PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update
Source: https://incomestatements.info
Category: Stock Reports